Aiming For Non-Statin Cholesterol Drug Market, Esperion Takes $33M
This article was originally published in The Pink Sheet Daily
Executive Summary
Spun out from Pfizer five years ago, the Ann Arbor, Mich., company hopes its Phase II candidate can capture a share of the market for high-cholesterol drugs prescribed to statin-intolerant patients.